Investigational drug · Phase 2
RG002C0106
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for IgA Nephropathy (IgAN).
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "RG002C0106"
First trial start
2025
Sep 8, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RG002C0106", any sponsor or status.
Conditions studied
As listed on its trial records.
- IgA Nephropathy (IgAN)
Approved drugs for the same conditions: IgA nephropathy · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "RG002C0106" as an intervention, largest first.
- A Phase 1 Study to Evaluate the Safety/Tolerability, PK/PD of RG002C0106 Injection in Healthy AdultsCompleted
Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.Industry
NCT06494527 · 50 participants · Start Oct 18, 2024 · Primary completion Aug 6, 2026
Drug: RG002C0106 · For: Safety Issues
Sites: Beijing, China
- Phase 1 Study to Evaluate RG002C0106 Injection in Healthy ParticipantsNot yet recruiting
Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.Industry
NCT07902245 · 30 participants (planned) · Start Dec 10, 2026 · Primary completion Mar 31, 2028
Drug: RG002C0106; 0.9% sodium chloride injection · For: Safety Issues
Sites: City of Lake Macquarie, Austria
- A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA NephropathyActive, not recruiting
Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.Industry
NCT07305974 · 30 participants (planned) · Start Sep 8, 2025 · Primary completion Mar 31, 2029
Drug: RG002C0106; placebo subcutaneous administration · For: IgA Nephropathy (IgAN)
Sites: Beijing, China
- A Study of RG002C0106 Injection in Adult Participants With Normal Renal Function and Mild-to-Moderate Renal ImpairmentActive, not recruiting
Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.Industry
NCT07445906 · 24 participants (planned) · Start Mar 15, 2026 · Primary completion Dec 1, 2026
Drug: RG002C0106 · For: Renal Impairments; IgA Nephropathy (IgAN)
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for IgA Nephropathy (IgAN)
- FUB523zigakibart, BION-1301Phase 36 trials
Novartis · IgA Nephropathy, Immunoglobulin A Nephropathy, IgA Nephropathy (IgAN)
- HSK39297Phase 35 trials
Haisco Pharmaceutical Group Co., Ltd. · IgA Nephropathy (IgAN), Paroxysmal Nocturnal Hemoglobinuria, Paroxysmal Nocturnal Haemoglobinuria (PNH)
- MY008211APhase 35 trials
Wuhan Createrna Science and Technology Co., Ltd · Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Nocturnal Hemoglobinuria, IgA Nephropathy (IgAN)
- JADE101Phase 32 trials
Jade Biosciences, Inc. · IgA Nephropathy (IgAN), IgA Nephropathy
- SC0062Phase 31 trial
Biocity Biopharmaceutics Co., Ltd. · IgA Nephropathy (IgAN)
- HSK39297 200mgQDPhase 23 trials
Haisco Pharmaceutical Group Co., Ltd. · IgA Nephropathy (IgAN), Lupus Nephritis (LN)
- HSK39297 300mgQDPhase 22 trials
Haisco Pharmaceutical Group Co., Ltd. · IgA Nephropathy (IgAN), Lupus Nephritis (LN)
- SGB-9768Phase 22 trials
Suzhou Sanegene Bio Inc. · PNH - Paroxysmal Nocturnal Hemoglobinuria, IgA Nephropathy (IgAN), C3 Glomerulopathy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.